TEPMETKO

Peak

tepotinib hydrochloride

NDAORALTABLETPriority Review

Approved

Feb 2021

Lifecycle

Peak

Competitive Pressure

8/100

Loss of Exclusivity

LOE Date

Mar 19, 2030

49 months away

Patent Expiry

Mar 19, 2030

Exclusivity Expiry

Feb 3, 2028

Patent Records (5)

Patent #	Expiry	Type	Use Code
9284300	Apr 29, 2028	Product	—
8921357	May 30, 2028	SubstanceProduct	—
9062029	Jul 4, 2028	Product	—
9403799	Jul 4, 2028		U-3077
8658643	Jul 4, 2028		U-3077

External Resources

Full prescribing information

FDA approval history

Drug nomenclature & identifiers